BACKGROUND: Insulin-like growth factor 1 receptor (IGF1R) plays important roles in the progression of pancreatic cancer. However, the underlying mechanism remains unclear. AIMS: The purpose of this study was to investigate the effects of IGF1R knockdown on the proliferation, apoptosis and chemosensitivity of pancreatic cancer cells, and explore the possible mechanisms. METHODS: Pancreatic cancer cells expressing IGF1R shRNA were established, and the cell proliferation, colony formation, and chemosensitivity to gemcitabine were examined in vitro. The activation of AKT and NF-κB was detected by Western blot analysis and luciferase assay, respectively. Xenograft mice models were established to evaluate the in vivo anti-tumor effects of IGF1R knockdown. RESULTS: IGF1R knockdown notably inhibited pancreatic cancer cell proliferation and colony formation, induced apoptosis, and inhibited xenograft tumor growth. Moreover, IGF1R knockdown significantly enhanced chemosensitivity to gemcitabine in pancreatic cancer cells, and this was correlated with the inhibition of PI3K/AKT and NF-κB pathways. CONCLUSIONS: IGF1R knockdown suppresses tumor growth and enhances chemosensitivity in pancreatic cancer via the inhibition of PI3K/AKT and NF-κB pathways, and is a promising approach to overcome the chemoresistance of pancreatic cancer.
BACKGROUND:Insulin-like growth factor 1 receptor (IGF1R) plays important roles in the progression of pancreatic cancer. However, the underlying mechanism remains unclear. AIMS: The purpose of this study was to investigate the effects of IGF1R knockdown on the proliferation, apoptosis and chemosensitivity of pancreatic cancer cells, and explore the possible mechanisms. METHODS:Pancreatic cancer cells expressing IGF1R shRNA were established, and the cell proliferation, colony formation, and chemosensitivity to gemcitabine were examined in vitro. The activation of AKT and NF-κB was detected by Western blot analysis and luciferase assay, respectively. Xenograft mice models were established to evaluate the in vivo anti-tumor effects of IGF1R knockdown. RESULTS:IGF1R knockdown notably inhibited pancreatic cancer cell proliferation and colony formation, induced apoptosis, and inhibited xenograft tumor growth. Moreover, IGF1R knockdown significantly enhanced chemosensitivity to gemcitabine in pancreatic cancer cells, and this was correlated with the inhibition of PI3K/AKT and NF-κB pathways. CONCLUSIONS:IGF1R knockdown suppresses tumor growth and enhances chemosensitivity in pancreatic cancer via the inhibition of PI3K/AKT and NF-κB pathways, and is a promising approach to overcome the chemoresistance of pancreatic cancer.
Authors: Hua Zhang; Deepali Sachdev; Chun Wang; Allison Hubel; Martine Gaillard-Kelly; Douglas Yee Journal: Breast Cancer Res Treat Date: 2008-04-17 Impact factor: 4.872
Authors: Bodo Schniewind; Matthias Christgen; Roland Kurdow; Sieglinde Haye; Bernd Kremer; Holger Kalthoff; Hendrik Ungefroren Journal: Int J Cancer Date: 2004-03-20 Impact factor: 7.396
Authors: Avital Lev; Amriti R Lulla; Jessica Wagner; Marie D Ralff; Joshua B Kiehl; Yan Zhou; Cyril H Benes; Varun V Prabhu; Wolfgang Oster; Igor Astsaturov; David T Dicker; Wafik S El-Deiry Journal: Oncotarget Date: 2017-09-12
Authors: Reham Abdel-Wahab; Gauri R Varadhachary; Priya R Bhosale; Xuemei Wang; David R Fogelman; Rachna T Shroff; Michael J Overman; Robert A Wolff; Milind Javle Journal: J Hematol Oncol Date: 2018-05-30 Impact factor: 17.388
Authors: Sameer A Dhayat; Wolf Arif Mardin; Jochen Seggewiß; Anda Jana Ströse; Christiane Matuszcak; Richard Hummel; Norbert Senninger; Sören Torge Mees; Jörg Haier Journal: PLoS One Date: 2015-11-25 Impact factor: 3.240
Authors: Ayse Ceren Mutgan; H Erdinc Besikcioglu; Shenghan Wang; Helmut Friess; Güralp O Ceyhan; Ihsan Ekin Demir Journal: Mol Cancer Date: 2018-02-23 Impact factor: 27.401